- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07948720
Dexmedetomidine as an Adjuvant to Bupivacaine in Fascia Iliaca Block for Femoral Fracture Surgery Under General Anesthesia: A Dose-Finding Study (FIB-DEX)
Dexmedetomidine Added to Bupivacaine in Fascia Iliaca Block Combined With General Anesthesia for Femoral Fracture Surgery: A Dose-Finding Randomized Double-Blind Study
### Brief Summary
Femoral fractures can cause severe pain during and after surgery. Although fascia iliaca block is commonly used to relieve pain in patients undergoing femoral fracture surgery, the duration of pain relief may be limited.
Dexmedetomidine is a medication that may prolong the pain-relieving effect of local anesthetics such as bupivacaine. However, the most appropriate dose of dexmedetomidine for this type of nerve block is not yet clearly established.
This study aims to determine the lowest effective dose of dexmedetomidine when added to bupivacaine for ultrasound-guided fascia iliaca block in patients undergoing femoral fracture surgery under general anesthesia.
The study includes 90 adult patients, aged 18-75 years, who are scheduled for femoral fracture surgery. Participants will be randomly assigned to one of three groups, with 30 patients in each group. All patients will receive general anesthesia and an ultrasound-guided fascia iliaca block containing 30 mL of 0.25% bupivacaine, combined with one of the following doses of dexmedetomidine:
- Group A: 0.5 micrograms/kg.
- Group B: 0.75 micrograms/kg.
- Group C: 1 microgram/kg.
Neither the patients nor the doctors assessing the study outcomes will know which dose has been administered.
Pain levels will be assessed during the first 24 hours after surgery using a numerical pain scale. The study will also measure the time until patients first require additional pain medication and the total amount of pain medication used.
Other assessments will include leg muscle strength, level of sedation, heart rate, blood pressure, and any possible side effects or complications.
The main purpose of this study is to identify the lowest dose of dexmedetomidine that provides effective postoperative pain relief while minimizing unwanted effects, helping improve pain management and recovery after femoral fracture surgery.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Alaa Taha, MD
- Telefonní číslo: +201276143115
- E-mail: Alaa.Taha@kasralainy.edu.eg
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
Age between 18-75 years. both sexes. American Society of Anesthesiologists (ASA) physical status I-III Scheduled for femoral fracture surgery
Exclusion Criteria:
Allergy to study drugs. Heart block type II. Pre-existing neurologic or psychiatric disease. Severe hepatic or renal impairment. Infection at injection site.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: dexmedetomidine 0.5
Name: Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia |
Intervention 1 - Group dexmeditomidine 0.5 Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. ---
Ostatní jména:
|
|
Aktivní komparátor: dexmedetomidine 0.75
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
|
Aktivní komparátor: dexmedetomidine 1
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesi |
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Time to the first request for rescue analgesia in minutes
Časové okno: from end of surgery to the first request for nalbuphine
|
time in minutes to first rescue analgesia will be measured. |
from end of surgery to the first request for nalbuphine
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
postoperative pain assessed as Numerical rating score (NRS)
Časové okno: from 30 minutes after surgery to 24 hours after surgery
|
from 30 minutes after surgery to 24 hours after surgery
|
|
|
motor block using modified bromage scale
Časové okno: from 30 minutes to 24 hours after surgery
|
from 30 minutes to 24 hours after surgery
|
|
|
total nalbuphine consumption in milligram (mg)
Časové okno: from end of surgery to 24 hours after surgery
|
from end of surgery to 24 hours after surgery
|
|
|
heart rate
Časové okno: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
sedation score
Časové okno: from 30 minutes after the end of operations to 24 hours postoperative .
|
using ramsay sedation scale |
from 30 minutes after the end of operations to 24 hours postoperative .
|
|
mean arterial pressure
Časové okno: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
systolic blood pressure
Časové okno: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
diastolic blood pressure
Časové okno: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- MS-228-2026
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .